03 0.74–1.41 Prostate 177 82 0.95 0.76–1.18 – – – 82 0.95 0.76–1.18 Kidney 180 10 1.06 0.51–1.94 19 1.03 0.62–1.60 29 1.04 0.69–1.49 Bladder 181 18 0.86 0.51–1.36 20 0.98 0.60–1.52 38 0.92 0.65–1.26 Melanoma 190 10 0.76 0.37–1.40 17 0.52 0.30–0.83 27 0.59 0.39–0.86 Other skin 191 19 1.15 0.69–1.80 18 0.63 0.37–0.99 37 0.82 0.58–1.13 Brain, medulla 193 9 0.97 0.44–1.83 27 1.00 0.66–1.45 36 0.99 0.69–1.37 Thyroid 194 1 0.72 0.02–4.03 6 0.71 0.26–1.54 7 0.71

0.29–1.47 Other IAP inhibitor endocrine glands 195 5 1.35 0.44–3.14 20 0.95 0.58–1.47 25 1.01 0.65–1.49 Connective tissue 197 2 0.91 0.11–3.28 9 1.77 0.81–3.36 11 1.51 0.75–2.70 Other and unspecified 199 12 1.31 0.67–2.28 29 0.92 0.61–1.31 41 1.00 0.72–1.36 Non-Hodgkin’s Selleck PI3K Inhibitor Library lymphoma 200, 202 23 2.05 1.30–3.07 4EGI-1 research buy 26 1.07 0.70–1.57 49 1.38 1.02–1.82 Hodgkin’s lymphoma 201 4 2.88 0.79–7.38 0 – 0.00–1.64 4 1.10 0.30–2.81 Multiple

myeloma 203 3 0.71 0.15–2.09 8 0.82 0.36–1.62 11 0.79 0.39–1.41 Lymphoid leukaemia 204 5 1.29 0.42–3.01 6 0.86 0.32–1.87 11 1.01 0.51–1.81 Myeloid leukaemia 205 5 1.64 0.53–3.83 6 0.82 0.30–1.77 11 1.06 0.53–1.89 aOverall no. of person-years 188,094 (men 55,798, women 132,296) Lung cancer rates were elevated in the cohort, with an overall SIR of 1.32 (95% CI 1.07–1.60), primarily due to increased incidence of the disease in men (SIR 1.45; 95% CI 1.03–1.98). There was also a significant increase in the incidence of non-Hodgkin’s lymphoma (SIR 2.05; 95% CI 1.30–3.07) in male workers, and the point estimate was increased also for Hodgkin’s lymphoma in men, but the confidence interval was wide since only four cases were observed (SIR 2.88; 95% CI 0.79–7.38). Female workers showed no evidence of increased lymphoma risks. Cancer of the liver

and gallbladder was proportionally more common in men than in women with SIRs of 1.93 versus 0.86 (not significant) based on 11 and 15 observed cases, respectively. No cases of cancer of the oesophagus were observed in male workers versus 3.71 expected (data not in table), whereas Gemcitabine five cases in female workers gave an SIR of 1.33 (95% CI 0.43–3.10).